Rotigotine, marketed as Neupro, is a non-ergot dopamine agonist (DA) available as a transdermal therapeutic system (TTS).1 It was approved in 2007 for Parkinson's disease (PD)2 and in 2008 for Restless Leg Syndrome.3 It has high affinity for the D3/D2/D1 receptors.1 The TTS gives Rotigotine the advantage of direct entry into the systemic circulation bypassing the intestinal absorption and the first pass liver metabolism with stable plasma concentration leading to uniform symptomatic control. It is available in six different strengths in the market ranging from 1mg/24hr to 8 mg/24hr. This article is protected by copyright. All rights reserved.